Eloxx Pharmaceuticals, Inc.·4

Jan 28, 5:34 PM ET

Walts Alan Edmund 4

4 · Eloxx Pharmaceuticals, Inc. · Filed Jan 28, 2025

Insider Transaction Report

Form 4
Period: 2025-01-24
Transactions
  • Exercise/Conversion

    Common Stock

    2025-01-24+3,75016,692 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-01-243,7503,750 total
    Common Stock (3,750 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.

Documents

1 file
  • 4
    tm254730-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT